Nanoparticles in precision medicine for ovarian cancer: From chemotherapy to immunotherapy
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Nanoparticles in precision medicine for ovarian cancer: From chemotherapy to immunotherapy
Authors
Keywords
Ovarian cancer, Nanoparticles, Immunotherapy, Targeted drug delivery
Journal
INTERNATIONAL JOURNAL OF PHARMACEUTICS
Volume 591, Issue -, Pages 119986
Publisher
Elsevier BV
Online
2020-10-16
DOI
10.1016/j.ijpharm.2020.119986
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Antibody Response against Cowpea Mosaic Viral Nanoparticles Improves In Situ Vaccine Efficacy in Ovarian Cancer
- (2020) Sourabh Shukla et al. ACS Nano
- Cancer statistics, 2020
- (2020) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Advances in aggregatable nanoparticles for tumor-targeted drug delivery
- (2020) Wenqi Yu et al. CHINESE CHEMICAL LETTERS
- In vivo efficacy of bevacizumab-loaded albumin nanoparticles in the treatment of colorectal cancer
- (2020) Inés Luis de Redín et al. Drug Delivery and Translational Research
- Encapsulation for Cancer Therapy
- (2020) Xavier Montané et al. MOLECULES
- A tumor-to-lymph procedure navigated versatile gel system for combinatorial therapy against tumor recurrence and metastasis
- (2020) Lin Qin et al. Science Advances
- Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer
- (2019) Mary L. Disis et al. JAMA Oncology
- Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models
- (2019) Zebin Wang et al. Scientific Reports
- Nanotechnology and immunotherapy in ovarian cancer: tracing new landscapes
- (2019) Bruna Corradetti et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Targeting Ovarian Cancer Cells Overexpressing CD44 with Immunoliposomes Encapsulating Glycosylated Paclitaxel
- (2019) Apriliana Cahya Khayrani et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer
- (2019) J F Liu et al. ANNALS OF ONCOLOGY
- Antitumor Activity and Safety of Pembrolizumab in Patients with Advanced Recurrent Ovarian Cancer: Results from the Phase 2 KEYNOTE-100 Study
- (2019) U A Matulonis et al. ANNALS OF ONCOLOGY
- ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†
- (2019) N Colombo et al. ANNALS OF ONCOLOGY
- Dual Inhibitors-Loaded Nanotherapeutics that Target Kinase Signaling Pathways Synergize with Immune Checkpoint Inhibitor
- (2019) Anujan Ramesh et al. Cellular and Molecular Bioengineering
- Antineoplastic nano-lipobubbles for passively targeted ovarian cancer therapy
- (2019) Derusha Frank et al. COLLOIDS AND SURFACES B-BIOINTERFACES
- Detecting the mutational signature of homologous recombination deficiency in clinical samples
- (2019) Doga C. Gulhan et al. NATURE GENETICS
- Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1/2 and RAD51
- (2019) Alanna R. Kaplan et al. Science Translational Medicine
- Nanoformulation of Talazoparib Delays Tumor Progression and Ascites Formation in a Late Stage Cancer Model
- (2019) Paige Baldwin et al. Frontiers in Oncology
- Developing Body-Components-Based Theranostic Nanoparticles for Targeting Ovarian Cancer
- (2019) Ravit Edelman et al. Pharmaceutics
- Cisplatin-loaded PLGA nanoparticles for HER2 targeted ovarian cancer therapy
- (2019) Rossina Domínguez-Ríos et al. COLLOIDS AND SURFACES B-BIOINTERFACES
- Entrectinib: First Global Approval
- (2019) Zaina T. Al-Salama et al. DRUGS
- Ovarian Cancer Immunotherapy: Turning up the Heat
- (2019) Eleonora Ghisoni et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma
- (2019) Panagiotis A. Konstantinopoulos et al. JAMA Oncology
- Efficient identification of neoantigen-specific T-cell responses in advanced human ovarian cancer
- (2019) Song Liu et al. Journal for ImmunoTherapy of Cancer
- Development and application of hyaluronic acid in tumor targeting drug delivery
- (2019) Zhijian Luo et al. Acta Pharmaceutica Sinica B
- Molecular affinity rulers: systematic evaluation of DNA aptamers for their applicabilities in ELISA
- (2019) Michiko Kimoto et al. NUCLEIC ACIDS RESEARCH
- Recent progress in drug delivery
- (2019) Chong Li et al. Acta Pharmaceutica Sinica B
- Anti-Angiogenic Activity Of Bevacizumab-Bearing Dexamethasone-Loaded PLGA Nanoparticles For Potential Intravitreal Applications
- (2019) Jiaxin Liu et al. International Journal of Nanomedicine
- Nanoformulations of small molecule protein tyrosine kinases inhibitors potentiate targeted cancer therapy
- (2019) Yanlong Yin et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- Current strategies for different paclitaxel-loaded Nano-delivery Systems towards therapeutic applications for ovarian carcinoma: A review article
- (2019) Alaa M. Khalifa et al. JOURNAL OF CONTROLLED RELEASE
- A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma
- (2019) Apostolos Sarivalasis et al. Journal of Translational Medicine
- 18F-labeled magnetic nanoparticles for monitoring anti-angiogenic therapeutic effects in breast cancer xenografts
- (2019) Yanshu Wang et al. JOURNAL OF NANOBIOTECHNOLOGY
- Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer
- (2019) Joyce F. Liu et al. JAMA Oncology
- Immunotherapy with checkpoint inhibitors in patients with ovarian cancer: Still promising?
- (2019) Antonio González‐Martín et al. CANCER
- Co-Delivery of Curcumin and Paclitaxel by “Core-Shell” Targeting Amphiphilic Copolymer to Reverse Resistance in the Treatment of Ovarian Cancer
- (2019) Meng-Dan Zhao et al. International Journal of Nanomedicine
- Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials
- (2019) Robert C Doebele et al. LANCET ONCOLOGY
- Nanoparticles provide long-term stability of bevacizumab preserving its antiangiogenic activity
- (2018) Flávia Sousa et al. Acta Biomaterialia
- Nanoparticle co-delivery of wortmannin and cisplatin synergistically enhances chemoradiotherapy and reverses platinum resistance in ovarian cancer models
- (2018) Maofan Zhang et al. BIOMATERIALS
- Targeted iron nanoparticles with platinum-(IV) prodrugs and anti-EZH2 siRNA show great synergy in combating drug resistance in vitro and in vivo
- (2018) Chang Yu et al. BIOMATERIALS
- A photocleavable low molecular weight hydrogel for light-triggered drug delivery
- (2018) Qihong Liu et al. CHINESE CHEMICAL LETTERS
- p53-Reactive T Cells Are Associated with Clinical Benefit in Patients with Platinum-Resistant Epithelial Ovarian Cancer After Treatment with a p53 Vaccine and Gemcitabine Chemotherapy
- (2018) Nicola R. Hardwick et al. CLINICAL CANCER RESEARCH
- Paclitaxel and di-fluorinated curcumin loaded in albumin nanoparticles for targeted synergistic combination therapy of ovarian and cervical cancers
- (2018) Kaustubh A. Gawde et al. COLLOIDS AND SURFACES B-BIOINTERFACES
- Approved CAR T cell therapies: ice bucket challenges on glaring safety risks and long-term impacts
- (2018) Ping-Pin Zheng et al. DRUG DISCOVERY TODAY
- A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer
- (2018) Kathleen N Moore et al. Future Oncology
- Molecular mechanisms of drug resistance in ovarian cancer
- (2018) Leyla Norouzi-Barough et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Multifunctional nanoparticles for cancer immunotherapy: A groundbreaking approach for reprogramming malfunctioned tumor environment
- (2018) Samaresh Sau et al. JOURNAL OF CONTROLLED RELEASE
- Development and evaluation of novel tumor-targeting paclitaxel-loaded nano-carriers for ovarian cancer treatment: in vitro and in vivo
- (2018) Shu Yao et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Chemoresistance in ovarian cancer: exploiting cancer stem cell metabolism
- (2018) Shan-Shan Li et al. Journal of Gynecologic Oncology
- PARP Inhibitors in Ovarian Cancer
- (2018) Gloria Mittica et al. Recent Patents on Anti-Cancer Drug Discovery
- Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer
- (2018) Janos L. Tanyi et al. Science Translational Medicine
- PARP1 and PARP2 stabilise replication forks at base excision repair intermediates through Fbh1-dependent Rad51 regulation
- (2018) George E. Ronson et al. Nature Communications
- Sensitive and frequent identification of high avidity neo-epitope specific CD8+ T cells in immunotherapy-naive ovarian cancer
- (2018) Sara Bobisse et al. Nature Communications
- Plectin-targeted liposomes enhance the therapeutic efficacy of a PARP inhibitor in the treatment of ovarian cancer
- (2018) Siva Sai Krishna Dasa et al. Theranostics
- An Open-Label, Randomized, Parallel, Phase II Trial to Evaluate the Efficacy and Safety of a Cremophor-Free Polymeric Micelle Formulation of Paclitaxel as First-Line Treatment for Ovarian Cancer: A Korean Gynecologic Oncology Group Study (KGOG-3021)
- (2018) Shin-Wha Lee et al. Cancer Research and Treatment
- Elimination of established tumors with nanodisc-based combination chemoimmunotherapy
- (2018) Rui Kuai et al. Science Advances
- Harnessing albumin as a carrier for cancer therapies
- (2018) Ella N. Hoogenboezem et al. ADVANCED DRUG DELIVERY REVIEWS
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Topography of cancer-associated immune cells in human solid tumors
- (2018) Jakob Nikolas Kather et al. eLife
- PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness
- (2018) Jianfeng Shen et al. CANCER RESEARCH
- Melanin-based nanoparticles in biomedical applications: From molecular imaging to treatment of diseases
- (2018) Xinyu Wang et al. CHINESE CHEMICAL LETTERS
- Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
- (2018) Kathleen Moore et al. NEW ENGLAND JOURNAL OF MEDICINE
- Biodistribution, Safety and Organ Toxicity of Docetaxel-Loaded in HER-2 Aptamer Conjugated Ecoflex Nanoparticles in a Mouse Xenograft Model of Ovarian Cancer
- (2018) Erfaneh Ghassami et al. Recent Patents on Nanotechnology
- Co-delivery of paclitaxel and cisplatin in poly(2-oxazoline) polymeric micelles: Implications for drug loading, release, pharmacokinetics and outcome of ovarian and breast cancer treatments
- (2018) Xiaomeng Wan et al. BIOMATERIALS
- Mechanisms underlying acquired platinum resistance in high grade serous ovarian cancer - a mini review
- (2018) Mudra Binju et al. BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS
- Novel Nano-Therapeutic Approach Actively Targets Human Ovarian Cancer Stem Cells after Xenograft into Nude Mice
- (2017) Amoura Abou-ElNaga et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Paclitaxel-loaded hyaluronan solid nanoemulsions for enhanced treatment efficacy in ovarian cancer
- (2017) Joo-Eun Kim et al. International Journal of Nanomedicine
- Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study
- (2017) Jung-Min Lee et al. JOURNAL OF CLINICAL ONCOLOGY
- Extremely long tumor retention, multi-responsive boronate crosslinked micelles with superior therapeutic efficacy for ovarian cancer
- (2017) Wenwu Xiao et al. JOURNAL OF CONTROLLED RELEASE
- An open-label, multicenter, phase I trial of a cremophor-free, polymeric micelle formulation of paclitaxel combined with carboplatin as a first-line treatment for advanced ovarian cancer: a Korean Gynecologic Oncology Group study (KGOG-3016)
- (2017) Shin-Wha Lee et al. Journal of Gynecologic Oncology
- Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
- (2017) Elizabeth M Swisher et al. LANCET ONCOLOGY
- Photo-controlled aptamers delivery by dual surface gold-magnetic nanoparticles for targeted cancer therapy
- (2017) Jian Zhao et al. Materials Science & Engineering C-Materials for Biological Applications
- Phase II study of paclitaxel associated with lipid core nanoparticles (LDE) as third-line treatment of patients with epithelial ovarian carcinoma
- (2017) Silvia R. Graziani et al. MEDICAL ONCOLOGY
- Nanoparticles for modulating tumor microenvironment to improve drug delivery and tumor therapy
- (2017) Shu Yang et al. PHARMACOLOGICAL RESEARCH
- Dually folate/CD44 receptor-targeted self-assembled hyaluronic acid nanoparticles for dual-drug delivery and combination cancer therapy
- (2017) Liang Song et al. Journal of Materials Chemistry B
- Engineered fusion protein-loaded gold nanocarriers for targeted co-delivery of doxorubicin and erbB2-siRNA in human epidermal growth factor receptor-2+ ovarian cancer
- (2017) Rajesh Kotcherlakota et al. Journal of Materials Chemistry B
- Novel Soluplus ® —TPGS mixed micelles for encapsulation of paclitaxel with enhanced in vitro cytotoxicity on breast and ovarian cancer cell lines
- (2016) Ezequiel Bernabeu et al. COLLOIDS AND SURFACES B-BIOINTERFACES
- PARP inhibitor combination therapy
- (2016) Amy Dréan et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Homologous recombination deficiency and ovarian cancer
- (2016) Jonathan A. Ledermann et al. EUROPEAN JOURNAL OF CANCER
- Phase 1b safety study of farletuzumab, carboplatin and pegylated liposomal doxorubicin in patients with platinum-sensitive epithelial ovarian cancer
- (2016) Kenneth H. Kim et al. GYNECOLOGIC ONCOLOGY
- Intraperitoneal chemotherapy of ovarian cancer by hydrogel depot of paclitaxel nanocrystals
- (2016) Bo Sun et al. JOURNAL OF CONTROLLED RELEASE
- Dual CD44 and folate receptor-targeted nanoparticles for cancer diagnosis and anticancer drug delivery
- (2016) Jae-Young Lee et al. JOURNAL OF CONTROLLED RELEASE
- Precision targeted therapy of ovarian cancer
- (2016) Justin Sapiezynski et al. JOURNAL OF CONTROLLED RELEASE
- Acid-Activatable Versatile Micelleplexes for PD-L1 Blockade-Enhanced Cancer Photodynamic Immunotherapy
- (2016) Dangge Wang et al. NANO LETTERS
- Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
- (2016) Mansoor R. Mirza et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors
- (2016) Bing-Lan Zhang et al. Science China-Life Sciences
- Evaluation of the efficacy of paclitaxel with curcumin combination in ovarian cancer cells
- (2016) Zeng Liu et al. Oncology Letters
- New insights in the pathophysiology of ovarian cancer and implications for screening and prevention
- (2015) Farr R. Nezhat et al. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
- Self-assembled nanoscale coordination polymers carrying siRNAs and cisplatin for effective treatment of resistant ovarian cancer
- (2015) Chunbai He et al. BIOMATERIALS
- Telodendrimer nanocarrier for co-delivery of paclitaxel and cisplatin: A synergistic combination nanotherapy for ovarian cancer treatment
- (2015) Liqiong Cai et al. BIOMATERIALS
- Ovarian cancer targeted hyaluronic acid-based nanoparticle system for paclitaxel delivery to overcome drug resistance
- (2015) Liping Wang et al. DRUG DELIVERY
- Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer
- (2015) Carol Aghajanian et al. GYNECOLOGIC ONCOLOGY
- Pazopanib Maintenance Therapy in East Asian Women With Advanced Epithelial Ovarian Cancer
- (2015) Jae-Weon Kim et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Safety and Antitumor Activity of Anti–PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer
- (2015) Junzo Hamanishi et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeted delivery of platinum-taxane combination therapy in ovarian cancer
- (2015) Swapnil S. Desale et al. JOURNAL OF CONTROLLED RELEASE
- Lipid-dendrimer hybrid nanosystem as a novel delivery system for paclitaxel to treat ovarian cancer
- (2015) Yuanjie Liu et al. JOURNAL OF CONTROLLED RELEASE
- Functional fluorescent nonporous silica nanoparticles as carriers for Pt(IV) anticancer prodrugs
- (2015) Mauro Ravera et al. JOURNAL OF INORGANIC BIOCHEMISTRY
- Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial
- (2015) Amit M Oza et al. LANCET ONCOLOGY
- Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial
- (2015) Sandro Pignata et al. LANCET ONCOLOGY
- Multifunctional Polymeric Micelles Co-loaded with Anti-Survivin siRNA and Paclitaxel Overcome Drug Resistance in an Animal Model of Ovarian Cancer
- (2015) G. Salzano et al. MOLECULAR CANCER THERAPEUTICS
- In situ vaccination with cowpea mosaic virus nanoparticles suppresses metastatic cancer
- (2015) P. H. Lizotte et al. Nature Nanotechnology
- Ovarian Cancer Immunotherapy Using PD-L1 siRNA Targeted Delivery from Folic Acid-Functionalized Polyethylenimine: Strategies to Enhance T Cell Killing
- (2015) Pei Yun Teo et al. Advanced Healthcare Materials
- Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
- (2014) Eric Pujade-Lauraine et al. JOURNAL OF CLINICAL ONCOLOGY
- Incorporation of Pazopanib in Maintenance Therapy of Ovarian Cancer
- (2014) Andreas du Bois et al. JOURNAL OF CLINICAL ONCOLOGY
- Ovarian cancer
- (2014) Gordon C Jayson et al. LANCET
- Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
- (2014) Joyce F Liu et al. LANCET ONCOLOGY
- Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
- (2014) Jonathan Ledermann et al. LANCET ONCOLOGY
- An update on PARP inhibitors—moving to the adjuvant setting
- (2014) Amir Sonnenblick et al. Nature Reviews Clinical Oncology
- Co-Delivery of Doxorubicin and siRNA with Reduction and pH Dually Sensitive Nanocarrier for Synergistic Cancer Therapy
- (2014) Weicai Chen et al. Small
- Apoptosis and Molecular Targeting Therapy in Cancer
- (2014) Mohamed Hassan et al. Biomed Research International
- Epigenetic Potentiation of NY-ESO-1 Vaccine Therapy in Human Ovarian Cancer
- (2014) K. Odunsi et al. Cancer Immunology Research
- Control of the Immune Response by Pro-Angiogenic Factors
- (2014) Thibault Voron et al. Frontiers in Oncology
- Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology
- (2013) Nicolas Bertrand et al. ADVANCED DRUG DELIVERY REVIEWS
- Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer
- (2013) Deborah K. Armstrong et al. GYNECOLOGIC ONCOLOGY
- Modulation of OATP1B-Type Transporter Function Alters Cellular Uptake and Disposition of Platinum Chemotherapeutics
- (2013) C. S. Lancaster et al. MOLECULAR CANCER THERAPEUTICS
- Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
- (2013) J. Murai et al. MOLECULAR CANCER THERAPEUTICS
- HER2 Expression Beyond Breast Cancer: Therapeutic Implications for Gynecologic Malignancies
- (2013) Diana P. English et al. Molecular Diagnosis & Therapy
- The potentials of nanotechnology-based drug delivery system for treatment of ovarian cancer
- (2013) Bina Gidwani et al. Artificial Cells Nanomedicine and Biotechnology
- The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy
- (2012) L. C. Hanker et al. ANNALS OF ONCOLOGY
- Liposomal paclitaxel formulations
- (2012) Štěpán Koudelka et al. JOURNAL OF CONTROLLED RELEASE
- Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission
- (2011) Christina S. Chu et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Curcumin Analogue CDF Inhibits Pancreatic Tumor Growth by Switching on Suppressor microRNAs and Attenuating EZH2 Expression
- (2011) B. Bao et al. CANCER RESEARCH
- Carboplatin Plus Paclitaxel Versus Carboplatin Plus Pegylated Liposomal Doxorubicin As First-Line Treatment for Patients With Ovarian Cancer: The MITO-2 Randomized Phase III Trial
- (2011) Sandro Pignata et al. JOURNAL OF CLINICAL ONCOLOGY
- Albumin: A versatile carrier for drug delivery
- (2011) Kinam Park JOURNAL OF CONTROLLED RELEASE
- Grand challenges in modulating the immune response with RNAi nanomedicines
- (2011) Meir Goldsmith et al. Nanomedicine
- Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
- (2011) Robert A. Burger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Coexpression of invasive markers (uPA, CD44) and multiple drug-resistance proteins (MDR1, MRP2) is correlated with epithelial ovarian cancer progression
- (2009) H Chen et al. BRITISH JOURNAL OF CANCER
- Phase II Evaluation of Nanoparticle Albumin–Bound Paclitaxel in Platinum-Sensitive Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer
- (2009) Michael G. Teneriello et al. JOURNAL OF CLINICAL ONCOLOGY
- A Synthetic Lethal Therapeutic Approach: Poly(ADP) Ribose Polymerase Inhibitors for the Treatment of Cancers Deficient in DNA Double-Strand Break Repair
- (2008) Alan Ashworth JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now